- Home
- QNRX vs TOVX Comparison
QNRX vs TOVX Comparison
Compare QNRX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- TOVX
- Stock Information
- Founded
- QNRX 2018
- TOVX 2001
- Country
- QNRX United States
- TOVX United States
- Employees
- QNRX N/A
- TOVX N/A
- Industry
- QNRX Medical/Dental Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- TOVX Health Care
- Exchange
- QNRX Nasdaq
- TOVX Nasdaq
- Market Cap
- QNRX 3.3M
- TOVX 3.8M
- IPO Year
- QNRX N/A
- TOVX 2006
- Fundamental
- Price
- QNRX $8.82
- TOVX $0.47
- Analyst Decision
- QNRX
- TOVX Hold
- Analyst Count
- QNRX 0
- TOVX 1
- Target Price
- QNRX N/A
- TOVX N/A
- AVG Volume (30 Days)
- QNRX 522.9K
- TOVX 1.8M
- Earning Date
- QNRX 05-13-2025
- TOVX 05-14-2025
- Dividend Yield
- QNRX N/A
- TOVX N/A
- EPS Growth
- QNRX N/A
- TOVX N/A
- EPS
- QNRX N/A
- TOVX N/A
- Revenue
- QNRX N/A
- TOVX N/A
- Revenue This Year
- QNRX N/A
- TOVX N/A
- Revenue Next Year
- QNRX N/A
- TOVX N/A
- P/E Ratio
- QNRX N/A
- TOVX N/A
- Revenue Growth
- QNRX N/A
- TOVX N/A
- 52 Week Low
- QNRX $5.01
- TOVX $0.40
- 52 Week High
- QNRX $54.95
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- QNRX 57.93
- TOVX 29.91
- Support Level
- QNRX $8.67
- TOVX $0.43
- Resistance Level
- QNRX $9.30
- TOVX $0.54
- Average True Range (ATR)
- QNRX 0.62
- TOVX 0.05
- MACD
- QNRX 0.03
- TOVX 0.03
- Stochastic Oscillator
- QNRX 56.63
- TOVX 41.18
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.